Save
Role of vitamin D in the expression of TGFβ signalling in patients with relapsing remitting multiple sclerosis
Author(s): ,
A. Lozano-Ros
Affiliations:
Gregorio Marañón Institute of Sanitary Research
,
J.M. García-Domínguez
Affiliations:
Neurology
,
M.I. García-García
Affiliations:
Pharmacogenomic Laboratory. Department of Pharmacy
,
M.L. Martínez-Ginés
Affiliations:
Neurology
,
H. Goicochea-Briceño
Affiliations:
Neurology Nursing, Gregorio Marañón Universitary Hospital, Madrid, Spain
,
J.P. Cuello
Affiliations:
Neurology
,
Y. Higueras
Affiliations:
Gregorio Marañón Institute of Sanitary Research
,
A. Meldaña-Rivera
Affiliations:
Gregorio Marañón Institute of Sanitary Research
L. López-Fernández
Affiliations:
Pharmacogenomic Laboratory. Department of Pharmacy
ECTRIMS Online Library. García-Domínguez J. Oct 12, 2018; 228921; P1080
José M García-Domínguez
José M García-Domínguez
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1080

Type: Poster Sessions

Abstract Category: Pathology and pathogenesis of MS - Immunology

Objective: Vitamin D (VD) has an important but ill-defined role in the regulation of the immune system. SMAD7, ERK1 and ZMIZ1 are representative of the TGFβ signalling pathways implicated in the differentiation of Th1 and Th17 responses. Our aim is to study the role of VD on the expression these genes in patients with relapsing remitting multiple sclerosis (RRMS).
Material and methods: Patients with RRMS and insufficient VD serum levels (< 30ng/ml) were included. At baseline, patients were supplemented with Calcifediol 0.266 mg/monthly as by clinical practice. CD4+ peripheral blood lymphocytes were obtained at baseline, months one and six after supplementation. Changes in mRNA expression of SMAD7, ERK1 and ZMIZ1 were measured by qPCR of the cDNA in the isolated lymphocytes using 2-ΔΔCt method. False discovery rate was applied to P values using Benjamini-Hochberg correction.
Results: Twenty-two stable patients, all on disease modifying treatment (DMT), were included. Median baseline VD level was 24.3ng/ml. The median VD level was 35.9ng/ml at month one and 32.4ng/ml at month 6. No differences in gene expression were found at month one. However, mRNA levels of ERK1 (1.5-fold, P=0.033) and SMAD7 (1.8-fold, P=0.033) were increased after 6 months of VD treatment. We found no changes on ZMIZ1 expression. Stratification by DMTs did not show any differences.
Conclusions: VD regulates the signalling pathway of TGFβ via SMAD7 and ERK1 in patients with RRMS. The late regulatory effect on SMAD7 and ERK1 seen after the normalization of serum levels of VD could mediate the antiinflammatory properties of VD by modulating the action of TGFβ and Th17 differentiation.
Disclosure: the authors declare that they do not have conflicts of interest

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings